Corbus Pharmaceuticals Holdings Inc. shares progressed 3.65% to $1.42 Monday. This proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.06% to 14,681.07 and the Dow Jones Industrial Average DJIA falling 0.28% to 34,838.16.
Corbus Pharmaceuticals Holdings Inc. closed $8.36 below its 52-week high ($9.78), which the company achieved on August 31st. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Fate Therapeutics Inc. FATE rose 2.75% to $85.08, Vanda Pharmaceuticals Inc. VNDA rose 3.68% to $16.91, and Viking Therapeutics Inc. VKTX fell 1.46% to $6.06.
The Pharmaceuticals is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2021. This widely-known consensus outlook gives a good sense of the company’s earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.